Stockscreener 앱 받기
31.17
0.87%
0.27
시간 외 거래:
30.57
-0.60
-1.92%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Growth Review: Is Capricor Therapeutics Inc a defensive stock2026 EndofYear Setup & Long-Term Safe Return Strategies - baoquankhu1.vn
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Capricor Therapeutics Pipeline Overview: Deramiocel for Muscular Dystrophy and Exosome-Based Vaccine Development (2025-2026) - Minichart
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insight - GuruFocus
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - 富途牛牛
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Insider Monkey
Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26) - TradingView
Deramiocel DMD program and big Nippon Shinyaku deals at Capricor (NASDAQ: CAPR) - Stock Titan
About Capricor Therapeutics (Ondo Tokenized) - Coinbase
13 Best Hot Stocks to Buy According to Analysts - Insider Monkey
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript - Insider Monkey
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data - Sahm
Q1 Earnings Forecast for CAPR Issued By HC Wainwright - MarketBeat
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? - Yahoo Finance
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative - simplywall.st
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $ - GuruFocus
Capricor Therapeutics Nears Key Milestones After Earnings Call - TipRanks
Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics (CAPR) Shares Recommended for Purchase Ami - GuruFocus
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss - marketscreener.com
B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $63 | CAPR Stock News - GuruFocus
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
CAPR: Piper Sandler Raises Price Target to $58, Reiterates Overw - GuruFocus
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3%Time to Sell? - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler - MarketBeat
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
Trading the Move, Not the Narrative: (CAPR) Edition - Stock Traders Daily
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR) - The Globe and Mail
Cantor Fitzgerald Remains a Buy on Capricor Therapeutics (CAPR) - The Globe and Mail
B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating - marketscreener.com
Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone - MSN
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - Sahm
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial Challenges - GuruFocus
Capricor Therapeutics (CAPR) Advances Duchenne Therapy with FDA Review - GuruFocus
Capricor Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Capricor (CAPR) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts - Investing.com Nigeria
Capricor Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts By Investing.com - Investing.com UK
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Capricor Looks Ahead To Deramiocel Approval In DMD - Citeline News & Insights
Capricor Therapeutics falls on Q4 earnings miss By Investing.com - Investing.com Canada
Capricor (CAPR) Focuses on Deramiocel's Approval Amid Financial Growth - GuruFocus
Capricor’s DMD therapy shows heart benefit in phase 3 trial | Tap to know more | Inshorts - Inshorts
Capricor Therapeutics (NASDAQ:CAPR) Posts Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Capricor Therapeutics Q4 Loss Widens - marketscreener.com
CAPRICOR THERAPEUTICS ($CAPR) Releases Q4 2025 Earnings - Quiver Quantitative
Capricor: Q4 Earnings Snapshot - marketscreener.com
Earnings Flash (CAPR) Capricor Therapeutics Posts Q4 Loss $-0.62, vs. FactSet Est of Loss of $-0.55 - marketscreener.com
Fourth quarter and full year 2025 earnings released, Capricor Therapeutics, Inc. outlines - Traders Union
1.20%
0.06%
자본화:
|
볼륨(24시간):